Published in Front Immunol on June 30, 2017
Immunology of tuberculosis. Annu Rev Immunol (2001) 14.26
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (1998) 10.78
Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med (1999) 8.80
Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res (2001) 5.78
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
Curcumin: the Indian solid gold. Adv Exp Med Biol (2007) 4.12
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med (2011) 3.60
Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med (1998) 3.42
Tuberculosis: latency and reactivation. Infect Immun (2001) 3.15
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res (2001) 2.69
Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J (2012) 2.42
The immunological life cycle of tuberculosis. Nat Rev Immunol (2012) 2.25
Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature (2009) 2.13
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal (2008) 1.99
Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ (2008) 1.85
Will tuberculosis become resistant to all antibiotics? Proc Biol Sci (2001) 1.79
Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis (2013) 1.69
Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2002) 1.69
Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol (1998) 1.66
High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa. Emerg Infect Dis (2007) 1.65
Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Respir J (2009) 1.53
Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med (2007) 1.51
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest (2005) 1.48
Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner. PLoS Pathog (2011) 1.46
Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med (2013) 1.20
In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun (2000) 1.19
High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J (2005) 1.16
World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis (2012) 1.15
Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur J Med Chem (2010) 1.13
Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A (2015) 1.08
Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir Med (1999) 1.07
Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Negl Trop Dis (2012) 1.02
Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: evidence of its antioxidant property. Exp Toxicol Pathol (2010) 1.02
Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling. J Biol Chem (2011) 0.98
Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv (2011) 0.98
Role of curcumin in health and disease. Arch Physiol Biochem (2008) 0.98
T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS One (2011) 0.97
The Persistence of Tuberculous Infections. Am J Pathol (1933) 0.96
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials (2010) 0.92
Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health (2012) 0.92
Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother (2015) 0.91
Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes. J Immunol (2009) 0.90
Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World J Gastroenterol (2008) 0.90
Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J Biol Chem (2014) 0.87
A preliminary report on the use of B663 in the treatment of Chinese leprosy patients with chronic reaction. Lepr Rev (1968) 0.87
Isoniazid induces apoptosis of activated CD4+ T cells: implications for post-therapy tuberculosis reactivation and reinfection. J Biol Chem (2014) 0.81
[Synergistic effect of rifampicin on hepatotoxicity of isoniazid]. Antibiot Med Biotekhnol (1985) 0.79
Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities. Phytother Res (2012) 0.78
Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis. Eur J Med Chem (2015) 0.77
Blockade of the Kv1.3 K+ Channel Enhances BCG Vaccine Efficacy by Expanding Central Memory T Lymphocytes. J Infect Dis (2016) 0.76
Clofazimine (lamprene or B663) in lepra reactions. Lepr Rev (1981) 0.76
Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection. Respirology (2016) 0.76
Clofazimine (Lamprene, B663) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases, 1966-1978. Int J Lepr Other Mycobact Dis (1981) 0.76
The immunopharmacology of antileprosy agents. Lepr Rev (1983) 0.76
Meeting report: The International Conference on Human Immunity to Tuberculosis. Tuberculosis (Edinb) (2012) 0.76
The treatment of corticosteroid-dependent lepromatous patients in persistent Erythema nodosum leprosum with clofazimine. Lepr Rev (1973) 0.76
Heightened inflammation in severe malaria is associated with decreased IL-10 expression levels and neutrophils. Innate Immun (2014) 0.88
Cellular Architecture of Spinal Granulomas and the Immunological Response in Tuberculosis Patients Coinfected with HIV. Front Immunol (2017) 0.75
Reply to Levis and Rendini. J Infect Dis (2017) 0.75